TriSalus Life Sciences announced the appointment of Scott Davie to the role of Chief Technology Officer, deepening the company’s leadership capabilities as it builds an integrated therapeutic/drug delivery portfolio.
As chief technology officer, Scott Davie will oversee research and development of the company’s intravascular infusion systems powered by its proprietary Pressure Enabled Drug Delivery™ (PEDD™) approach with SmartValve™ technology, as well as operations, pre-clinical execution, and management of the IP portfolio. A 25-year veteran of the medical device industry across multiple industry segments, Davie also will serve as site lead for the company’s Westminster, CO facility and report to the company’s President and Chief Executive Officer, Mary Szela.
“We’re thrilled to add Scott’s deep experience in medical device development and commercialization to the critical work underway at TriSalus. Our PEDD-based products have tremendous promise for treating solid tumors, and under his knowledge and leadership skills, we’re poised to help lead a transformation in cancer care,” said Szela. “Additionally, his experience in the U.S., Canadian, and Japanese markets is essential to supporting our global development efforts.”
Prior to joining TriSalus Life Sciences, Davie held a number of leadership positions at Medtronic creating and leading teams and engineering departments. He has delivered innovative, complex, therapeutic and diagnostic systems from conceptualization through market launch including implantable cardiac devices, AF ablation systems, and hospital based diagnostic platforms. His regulatory experience spans filings and registrations via 510k’s, PMA supplements, original PMAs, and CE Marks.
Davie earned his Bachelor of Science in Mechanical Engineering from MIT and his Master of Science in Mechanical Engineering from Stanford with a focus on Biomechanics and Electronics.
“As someone who’s watched cancer cut family members’ lives short, I am thrilled to be part of the TriSalus team and embrace the opportunity to dramatically improve therapeutic delivery and outcomes for these cancer patients,” said Davie.